"US transcatheter tricuspid valve repair market grows by over 50% since launch in Q2 2024" was originally created and ...

JenaValve announced today that it received the green light to begin a new randomized controlled trial for its Trilogy device.

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, showcased 2-year follow up data from the ALIGN-AR Trial at TCT 2024. Concurrently, the ...

Zoom in or out of the page as needed for optimal reading comfort. You can also use a pinch gesture to zoom on touch devices.